A
Auscan Bio / 澳斯康生物
Biologics CDMO and serum-free cell-culture media (Nantong)
About Auscan Bio / 澳斯康生物
Auscan Biopharmaceuticals / Thousand Oaks Biopharmaceuticals (澳斯康生物, TOBio) is a Nantong-headquartered biologics CDMO and cell-culture-media group founded around 2011–2017. Through JSBio it supplies serum-free media for recombinant proteins, antibodies, vaccines and cell therapy; through its CDMO arm it offers CMC from cell-line development through clinical and commercial GMP manufacturing for mAbs, bispecifics, ADCs and related modalities at Nantong and Shanghai Lingang sites that target FDA/EMA/NMPA standards. The company lists global footprints in Jiangsu, Shanghai, Gansu, Korea and the US and has been recognized as a China unicorn / specialized SME while serving 500+ biopharma customers.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Nantong, China
- Employees
- 46
- Open positions
- 2
- Dealroom signal
- 77.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Rumoured $1B, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Jan 2019
- Capital deployed
- $59M
- Preferred round
- SERIES A
Knowledge graph
News
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Jul 2022 | $0 | — | Timesbole | ↗ |
| SERIES DOther financing | Dec 2021 | $235M | $940M | CDH Investments · Highlight Capital · Hillhouse Capital · Goldstone Investment | ↗ |
Growth signals
Latest recorded traffic for Auscan Bio / 澳斯康生物 is 10 monthly website visits, down 98% over the last three months. Auscan Bio / 澳斯康生物's team grew 2.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Auscan Bio / 澳斯康生物 in the Nantong ecosystem
The Auscan Bio / 澳斯康生物 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
New Alliance Capital
BlueBay Asset Management- BCBinghong Capital
Addor Capital
CITIC Gold Stone Investment
CICC- GIGoldstone Investment
Series B and later5 investors entered at this stage
GL Ventures- CFCapital Venture Investment Fund
CDH Investments
Highlight Capital
Hillhouse Capital
Other known investors1 additional known investor
Timesbole
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Auscan Bio / 澳斯康生物 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Auscan Bio / 澳斯康生物’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.